Alzheimer's disease drug development pipeline: 2026
Jeffrey L Cummings1,2, Yadi Zhou3, Yuxin Yang3
1Chambers-Grundy Center for Transformative Neuroscience, Department of Brain Health, Kirk Kerkorian School of Medicine University of Nevada, Las Vegas (UNLV) Las Vegas Nevada USA.
Alzheimer'S & Dementia (New York, N. Y.)
|May 7, 2026
Summary
The Alzheimer's disease (AD) drug development pipeline is expanding, with 158 drugs in 192 trials targeting diverse pathophysiological processes. This includes disease-targeting and symptom-targeting therapies, with significant industry sponsorship, particularly in Phase 3 trials.
Area of Science:
- Neurology
- Pharmacology
- Clinical Trials
Background:
- Urgent need for novel Alzheimer's disease (AD) therapies due to the increasing global AD population.
- ClinicalTrials.gov serves as a crucial resource for tracking drugs in development for AD treatment.
Purpose of the Study:
- To analyze the current landscape of drugs and clinical trials for Alzheimer's disease.
- To categorize therapeutic approaches and identify key sponsors in AD drug development.
Main Methods:
- Systematic review of data from ClinicalTrials.gov for Alzheimer's disease.
- Categorization of drugs by therapeutic class (small molecule, biologic, symptom-targeted) and development phase.
- Analysis of trial sponsorship and participant numbers.
Main Results:
- 158 drugs are currently in 192 AD clinical trials.
- Therapeutic agents include 39% small molecule disease-targeting therapies (DTTs), 34% biologic DTTs, and 28% symptom-targeted therapies (STTs).
- The biopharmaceutical industry sponsors 59% of AD trials, including 72% of Phase 3 trials, which require 38,417 participants.
Conclusions:
- The Alzheimer's disease drug development pipeline shows significant growth in both the number of drugs and trials.
- A wide range of AD pathophysiological processes are being targeted by investigational therapies.
- Repurposed drugs constitute a substantial portion (35%) of agents in development, indicating a viable strategy for accelerating AD treatment discovery.
Related Concept Videos
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:15Drug Dosing: Geriatric Patients
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
01:30Dementia
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
The progression of dementia is generally gradual.